why choose us

Clinical Trials Search

Showing 15,400 of 132,963 result(s)
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Status: NOT_YET_RECRUITING

Condition: Ototoxicity, Drug-Induced

Interventions: High-dose intervention (30mg daily)

Date: 2023-02-07

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Status: Completed

Condition: Smoking Cessation

Interventions: 150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Date: 2023-02-07

Promising ROd-cone DYstrophy Gene therapY

Status: Completed

Condition: Retinitis Pigmentosa

Interventions: AAV-RdCVF-RdCVFL

Date: 2023-02-07

A Study of Virtually Supervised Mouthwash and Interdental Brushes

Status: COMPLETED

Condition: Healthy

Interventions: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Date: 2023-02-07

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Status: ACTIVE_NOT_RECRUITING

Condition: Presbyopia

Interventions: Combination ophthalmic solution of Aceclidine and Brimonidine

Date: 2023-02-07

Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer

Status: Completed

Condition: Prostate Cancer

Interventions: Apalutamide 240 mg by mouth daily for a total of 6-months.

Date: 2023-02-07

Trigeminal Evoked Responses to Improve Rhizotomy

Status: Completed

Condition: Trigeminal Neuralgia

Interventions: TGN patients recruited for this study will already be undergoing percutaneous rhizotomy surgery.
TSEPs will be measured at baseline prior to surg

Date: 2023-02-07

Achieving Diagnostic Excellence Through Prevention and Teamwork

Status: NOT_YET_RECRUITING

Condition: Diagnostic Errors

Interventions: Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality a

Date: 2023-02-07

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Status: Completed

Condition: Psoriasis

Interventions: Specified dose on specified days

Date: 2023-02-07

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Status: Completed

Condition: Small Cell Lung Cancer (SCLC)

Interventions: Tarlatamab will be administered as an IV infusion.

Date: 2023-02-07